SnapSlide, LLC, a packaging innovations company dedicated to making it easier for consumers to access, use, and store pharmaceutical products, has introduced a line of no-torque, child-resistant caps that is the market’s first adaptive packaging solution. SnapSlide’s ergonomic design features a patented, sliding, two-step opening procedure that allows for single-handed opening and closing while maintaining […]
TreeFrog Therapeutics, a cell therapy development company with its leading Parkinson’s disease program, is presenting for the first time at the annual meeting of the American Academy of Neurology, which will take place in Denver, Colorado from April 13-18, 2024. Parkinson’s disease is a complex neurodegenerative disorder that affects more than 10 million people worldwide and is […]
BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal. Improvements in non-motor symptoms correlated […]
Amprion is pleased to be affiliated with a new scientific paper published in Alzheimer’s & Dementia, entitled “Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay,” led by University of Perugia Professor, Dr. Lucilla Parnetti and Amprion Director of Research and Development, Dr. Luis Concha-Marambio. In this study, the α-Synuclein Seed Amplification Assay […]
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD). The original NDA for IPX203 resulted in a Complete Response […]
AbbVie (NYSE: ABBV) today announced the launch of PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement), and when available combinations of Parkinson’s medicinal products have not given satisfactory results.1 PRODUODOPA is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for […]
Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorisation (CTA) for Mission to commence its multi-part, adaptive Phase 1, first-in-human study evaluating the safety and tolerability of MTX325, intended for the treatment of […]
Surgical Information Sciences, a medical device company focused on improved visualization of brain structures for deep brain stimulation (DBS) surgery, announced the commencement of its post-market study, the Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson’s Disease (VISION Study). This study aims to evaluate the potential of SIS technology in […]
